About Evotec SE
Evotec (ETR:EVT), (NASDAQ:EVO) is a biotechnology company dedicated to drug discovery and development services. It engages in partnerships with pharma and biotech for drug discovery, leverages a broad range of therapeutic areas, and offers a suite of technology platforms to progress its projects from research through to commercialization. With a focus on innovation in drug discovery, Evotec aims to develop novel therapeutic options for diseases with unmet medical needs. Its operations span from early-stage discovery to pre-clinical development, incorporating a variety of projects across different therapeutic areas including neuroscience, diabetes, oncology, and infectious diseases, among others. Evotec's objective is to create value by accelerating the drug development process, reducing costs for its partners, and ultimately delivering more effective treatments to improve patient outcomes.
Snapshot
Operations
Products and/or services of Evotec SE
- Drug discovery and development services: Offers end-to-end integrated drug discovery and development services, leveraging advanced technologies like AI.
- Just - Evotec Biologics: Provides integrated design, development, and manufacturing services for biologics, focusing on efficiency and cost-effectiveness.
- Bridging the innovation gap: Collaborates with academic, biotech, and pharmaceutical partners to transform early-stage research into drug discovery projects.
- EVOcells: Focuses on cell therapy projects, including the development of iPSC-based therapies, aiming to treat serious diseases.
- Target-to-Clinic Platform: Accelerates drug discovery through a comprehensive suite of capabilities from target identification to clinical entry.
- BEOncology: Dedicated to discovering and developing new cancer therapies using a broad range of cutting-edge technologies.
Evotec SE executive team
- Dr. Christian Wojczewski Ph.D.CEO & Management Board Member
- Dr. Cord Dohrmann Ph.D.Chief Scientific Officer & Member of Management Board
- Ms. Aurelie DalbiezChief People Officer & Member of Management Board
- Mr. Paul HitchinCFO & Member of Management Board
- Dr. Sarah FakihExecutive VP, Head of Global Communications & Investor Relations
- Dr. Christian DargelEVP Global Head of Legal & Compliance
- Dr. Ian M. HunneyballSenior Vice President of Programme Management & Clinical Operations
- Dr. David HalletExecutive Vice President
- Uwe AndagEVP Head of Metabolic Diseases
- Ms. Christiane HonischSVP Head of Diagnostics